参考文献/References:
[1] Wang Z, Chen Z, Zhang L, et al. Status of hypertension in China:results from the China Hypertension Survey,2012—2015[J]. Circulation,2018,137(22):2344-2356.
[2] 方湘,潘小蓉,程毅松,等.《中青年高血压管理中国专家共识》解读[J]. 中国循证医学杂志,2020,20(7):753-758.
[3] Kitada K, Kobori H, Nishiyama A Liver-specific angiotensinogen suppression:an old yet novel target for blood pressure control through RAS inhibition?[J]. Hypertens Res,2014,37(5):393-394.
[4] Xu Y, Rong J, Zhang Z. The emerging role of angiotensinogen in cardiovascular diseases[J]. J Cell Physiol,2021,236(1):68-78.
[5] Zimmermann TS, Karsten V, Chan A, et al. Clinical proof of concept for a novel hepatocyte-targeting GalNAc-siRNA conjugate[J]. Mol Ther,2017,25(1):71-78.
[6] Arendse LB, Danser AHJ, Poglitsch M, et al. Novel therapeutic approaches targeting the renin-angiotensin system and associated peptides in hypertension and heart failure[J]. Pharmacol Rev,2019,71(4):539-570.
[7] Li HM, Du ZR, Zhang L, et al. The relationship between angiotensinogen gene polymorphisms and essential hypertension in a Northern Han Chinese population[J]. Angiology,2014,65(7):614-619.
[8] 陈娟,董昌武.原发性高血压与血管紧张素原基因多态性的相关性研究进展[J]. 黑龙江医药,201427(1):70-73.
[9] Heianza Y, Qi L. Impact of genes and environment on obesity and cardiovascular disease[J]. Endocrinology,2019,160(1):81-100.
[10] Kobori H, Urushihara M. Augmented intrarenal and urinary angiotensinogen in hypertension and chronic kidney disease[J]. Pflugers Arch,2013,465(1):3-12.
[11] Tao XR, Rong JB, Lu HS, et al. Angiotensinogen in hepatocytes contributes to Western diet-induced liver steatosis[J]. J Lipid Res,2019,60(12):1983-1995.
[12] Raghunathan S, Patel BM. Therapeutic implications of small interfering RNA in cardiovascular diseases[J]. Fundam Clin Pharmacol,2013,27(1):1-20.
[13] Springer AD, Dowdy SF. GalNAc-siRNA conjugates:leading the way for delivery of RNAi therapeutics[J]. Nucleic Acid Ther,2018,28(3):109-118.
[14] Ren LW, Mirabito Colafella KM, Bovée DM, et al. Targeting angiotensinogen with RNA-based therapeutics[J]. Curr Opin Nephrol Hypertens,2020,29(2):180-189.
[15] Lee K, Jang B, Lee YR, et al. The cutting-edge technologies of siRNA delivery and their application in clinical trials[J]. Arch Pharm Res,2018,41(9):867-874.
[16] Matsuda S, Kristofer K, Nair JK, et al. siRNA conjugates carrying sequentially assembled trivalent N-acetylgalactosamine linked through nucleosides elicit robust gene silencing in vivo in hepatocytes[J]. ACS Chem Biol,2015,10(5):1181-1187.
[17] Korin E, Bejerano T, Cohen S. GalNAc bio-functionalization of nanoparticles assembled by electrostatic interactions improves siRNA targeting to the liver[J]. J Control Release,2017,266:310-320.
[18] Ye F, Wang Y, Wu C, et al. Angiotensinogen and megalin interactions contribute to atherosclerosis-brief report[J]. Arterioscler Thromb Vasc Biol,2019,39(2):150-155.
[19] Mirabito Colafella KM, Bovée DM, Danser AHJ. The renin-angiotensin-aldosterone system and its therapeutic targets[J]. Exp Eye Res,2019,186:107680.
[20] Olearczyk J, Gao S, Eybye M, et al. Targeting of hepatic angiotensinogen using chemically modified siRNAs results in significant and sustained blood pressure lowering in a rat model of hypertension[J]. Hypertens Res,2014,37(5):405-412.
[21] Uijl E, Mirabito Colafella KM, Sun Y, et al. Strong and sustained antihypertensive effect of small interfering RNA targeting liver angiotensinogen[J]. Hypertension,2019,73(6):1249-1257.
[22] Mullick AE, Yeh ST, Graham MJ, et al. Blood pressure lowering and safety improvements with liver angiotensinogen inhibition in models of hypertension and kidney injury[J]. Hypertension,2017,70(3):566-576.
[23] Yiannikouris F, Wang Y, Shoemaker R, et al. Deficiency of angiotensinogen in hepatocytes markedly decreases blood pressure in lean and obese male mice[J]. Hypertension,2015,66(4):836-842.
[24] Matsusaka T, Niimura F, Shimizu A, et al. Liver angiotensinogen is the primary source of renal angiotensinⅡ[J]. J Am Soc Nephrol,2012,23(7):1181-1189.
[25] Carey RM. The intrarenal renin-angiotensin and dopaminergic systems:control of renal sodium excretion and blood pressure[J]. Hypertension,2013,61(3):673-680.
[26] Lu H, Cassis LA, Kooi CW, et al. Structure and functions of angiotensinogen[J]. Hypertens Res,2016,39(7):492-500.
[27] Haase N, Foster DJ, Cunningham MW, et al. RNA interference therapeutics targeting angiotensinogen ameliorate preeclamptic phenotype in rodent models[J]. J Clin Invest,2020,130(6):2928-2942.
[28] Zlatev I, Castoreno A,Brown CR, et al.Reversal of siRNA-mediated gene silencing in vivo[J]. Nat Biotechnol,2018,36(6):509-511.
[29] Mann JFE, B?hm M. Dual renin-angiotensin system blockade and outcome benefits in hypertension:a narrative review[J]. Curr Opin Cardiol,2015,30(4):373-377.